Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.
Cody PlastererShirng-Wern TsaihAmy R PeckInna ChervonevaCaitlin O'MearaYunguang SunAngela LemkeDana MurphyJennifer SmithSophia RanAlbert J KovatichJeffrey A HookeCraig D ShriverHai HuEdith P MitchellCarmen BergomAmit JoshiPaul AuerJeremy ProkopHallgeir RuiMichael J FlisterPublished in: Breast cancer research and treatment (2019)
Collectively, these data implicate NNAT as a novel mediator of cell proliferation and migration, which correlates with decreased tumorigenic potential and prolonged patient survival.